Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Jörger M, Sessa C, Stuedeli S, Levy N, Hafner P, Lane H, Larger P, Engelhardt M, Kaindl T, Volden M, Mark M, Mantiero M, Hess D, Metaxas Y, Stathis A, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. Invest New Drugs 2019
30.08.2019A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
30.08.2019Invest New Drugs 2019
Jörger Markus, Sessa Cristiana, Stuedeli Silvia, Levy Nicole, Hafner Peter, Lane Heidi, Larger Patrice, Engelhardt Marc, Kaindl Thomas, Volden Matthias, Mark Michael, Mantiero Mara, Hess Dagmar, Metaxas Yannis, Stathis Anastasios, von Moos Roger
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Hitz F, Driessen C, Mey U, Samaras P, Vilei S, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle T, Besse L, Hess D, Pabst T, Kraus M, Swiss Group for Clinical Cancer Research SAKK. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J 2019; 9:70.
27.08.2019Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
27.08.2019Blood Cancer J 2019; 9:70
Hitz Felicitas, Driessen Christoph, Mey U, Samaras P, Vilei S Berardi, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle Tobias, Besse Lenka, Hess Dagmar, Pabst T, Kraus Marianne, Swiss Group for Clinical Cancer Research SAKK
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
Hoyle A, Aebersold D, Jones R, Matheson D, Millman R, Mason M, Ritchie A, Russell M, Douis H, Parmar M, Sydes M, Clarke N, Gillessen Sommer S, Ingleby F, Ali A, James N, Cook A, Parker C, de Bono J, Attard G, Chowdhury S, Cross W, Dearnaley D, Brawley C, Gilson C, STAMPEDE Investigators. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. Eur Urol 2019; 76:719-728.
23.08.2019Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
23.08.2019Eur Urol 2019; 76:719-728
Hoyle Alex P, Aebersold Daniel M, Jones Rob J, Matheson David, Millman Robin, Mason Malcolm D, Ritchie Alastair W S, Russell Martin, Douis Hassan, Parmar Mahesh K B, Sydes Matthew R, Clarke Noel W, Gillessen Sommer Silke, Ingleby Fiona, Ali Adnan, James Nicholas D, Cook Adrian, Parker Christopher C, de Bono Johann S, Attard Gerhardt, Chowdhury Simon, Cross William R, Dearnaley David P, Brawley Christopher D, Gilson Clare, STAMPEDE Investigators
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 2019; 82:854-861.
23.08.2019BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
23.08.2019J Am Acad Dermatol 2019; 82:854-861
Hasan Ali Omar, Sadik Christian D, Zillikens Detlef, Schmidt Enno, Jochum Wolfram, Mani Bernhard, Cozzio Antonio, Braun Anne, Emtenani Shirin, Hammers Christoph, Abdou Marie-Therese, Diem Stefan, Fässler Mirjam, Berner Fiamma, Ring Sandra S, Bomze David, Flatz Lukas
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
Buechler S, Badve S, Leyland-Jones B, Viale G, Kammler R, Thürlimann B, Willis S, Gökmen-Polar Y, Gray K, Regan M. Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. JNCI Cancer Spectr 2019; 3:pkz051.
16.08.2019Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
16.08.2019JNCI Cancer Spectr 2019; 3:pkz051
Buechler Steven A, Badve Sunil S, Leyland-Jones Brian, Viale Giuseppe, Kammler Rosita, Thürlimann Beat, Willis Scooter, Gökmen-Polar Yesim, Gray Kathryn P, Regan Meredith M
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Schuler M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Schostak M, Park S, Cho B, Sayehli C, Navarro A, Soo R, Richly H, Cassier P, Tai D, Penel N, Nogova L, Jörger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019
09.08.2019Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
09.08.2019Lancet Oncol 2019
Schuler Martin, Gajate Pablo, Cathomas Richard, Rajagopalan Prabhu, Grevel Joachim, Bender Sebastian, Boix Oliver, Nogai Hendrik, Ocker Matthias, Ellinghaus Peter, Schostak Martin, Park Se Hoon, Cho Byoung Chul, Sayehli Cyrus Michael, Navarro Alejandro, Soo Ross A, Richly Heike, Cassier Philippe Alexandre, Tai David, Penel Nicolas, Nogova Lucia, Jörger Markus
Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
Silzle T, Blum S, Schuler E, Kaivers J, Rudelius M, Hildebrandt B, Gattermann N, Haas R, Germing U. Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. Blood Cancer J 2019; 9:63.
09.08.2019Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
09.08.2019Blood Cancer J 2019; 9:63
Silzle Tobias, Blum Sabine, Schuler Esther, Kaivers Jennifer, Rudelius Martina, Hildebrandt Barbara, Gattermann Norbert, Haas Rainer, Germing Ulrich
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019
Wöckel A, Rhiem K, Nitz U, Mundhenke C, Müller-Schimpfle M, Möbus V, Maass N, Lux M, Luftner D, Loibl S, Rody A, Schmidt M, Witzel I, Wenz F, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Schneeweiss A, Kümmel S, Kühn T, Krug D, Dall P, Budach W, Blohmer J, Bauerfeind I, Albert U, Janni W, Müller V, Thill M, Untch M, Diel I, Fasching P, Kreipe H, Kolberg-Liedtke C, Jackisch C, Huober J, Harbeck N, Hanf V, Gerber B, Friedrich M, Fehm T, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14:224-245.
06.08.2019AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019
06.08.2019Breast Care (Basel) 2019; 14:224-245
Wöckel Achim, Rhiem Kerstin, Nitz Ulrike, Mundhenke Christoph, Müller-Schimpfle Markus, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Luftner Diana, Loibl Sibylle, Rody Achim, Schmidt Marcus, Witzel Isabell, Wenz Frederik, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Schütz Florian, Schneeweiss Andreas, Kümmel Sherko, Kühn Thorsten, Krug David, Dall Peter, Budach Wilfried, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Janni Wolfgang, Müller Volkmar, Thill Marc, Untch Michael, Diel Ingo, Fasching Peter A, Kreipe Hans-Heinrich, Kolberg-Liedtke Cornelia, Jackisch Christian, Huober Jens, Harbeck Nadia, Hanf Volker, Gerber Bernd, Friedrich Michael, Fehm Tanja, Ditsch Nina
Forgiveness and Reconciliation Processes in Dying Patients With Cancer
Renz M, Büche D, Reichmuth O, Schuett Mao M, Renz U, Siebenrock R, Strasser F. Forgiveness and Reconciliation Processes in Dying Patients With Cancer. Am J Hosp Palliat Care 2019:1049909119867675.
05.08.2019Forgiveness and Reconciliation Processes in Dying Patients With Cancer
05.08.2019Am J Hosp Palliat Care 2019:1049909119867675
Renz Monika, Büche Daniel, Reichmuth O, Schuett Mao M, Renz U, Siebenrock R, Strasser Florian
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Hench I, Vlajnic T, Bubendorf L, Burg P, Tolnay M, Ruiz C, Rothermundt C, Püschel H, Mestre R, Mingrone W, Kremer E, Hermanns T, Hench J, Gillessen Sommer S, Fischer N, Costa L, Cathomas R, Sakk S. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). Cancers (Basel) 2019; 11
01.08.2019Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
01.08.2019Cancers (Basel) 2019; 11
Hench Ivana Bratic, Vlajnic Tatjana, Bubendorf Lukas, Burg Philippe Von, Tolnay Markus, Ruiz Christian, Rothermundt Christian, Püschel Heike, Mestre Ricardo Pereira, Mingrone Walter, Kremer Eloïse, Hermanns Thomas, Hench Jürgen, Gillessen Sommer Silke, Fischer Natalie, Costa Luigi, Cathomas Richard, Sakk Swiss Group For Clinical Cancer Research
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Huober J, Hackman J, Dasappa L, Ciruelos E, Toral Pena J, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber R, Piccart-Gebhart M, Jouannaud C, Wildiers H, Lecocq C, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Láng I, Smith I, Boyle F, Xu B, Di Cosimo S. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019; 118:169-177.
01.08.2019Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
01.08.2019Eur J Cancer 2019; 118:169-177
Huober Jens, Hackman John, Dasappa Lokanatha, Ciruelos Eva, Toral Pena Juan Carlos, Adamchuk Hryhoriy, Hickish Tamas, de la Pena Lorena, Jackisch Christian, Gelber Richard D, Piccart-Gebhart Martine, Jouannaud Christelle, Wildiers Hans, Lecocq Christophe, Holmes Eileen, Baselga José, de Azambuja Evandro, Untch Michael, Fumagalli Debora, Sarp Severine, Láng István, Smith Ian, Boyle Frances, Xu Binghe, Di Cosimo Serena
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019
Ditsch N, Schmidt M, Rody A, Rhiem K, Nitz U, Mundhenke C, Müller-Schimpfle M, Möbus V, Maass N, Lux M, Schneeweiss A, Schütz F, Wöckel A, Witzel I, Wenz F, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Luftner D, Loibl S, Kümmel S, Diel I, Dall P, Budach W, Blohmer J, Bauerfeind I, Albert U, Müller V, Janni W, Jackisch C, Fasching P, Fehm T, Kühn T, Krug D, Kreipe H, Kolberg-Liedtke C, Huober J, Harbeck N, Hanf V, Gerber B, Friedrich M, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14:247-255.
30.07.2019AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019
30.07.2019Breast Care (Basel) 2019; 14:247-255
Ditsch Nina, Schmidt Marcus, Rody Achim, Rhiem Kerstin, Nitz Ulrike, Mundhenke Christoph, Müller-Schimpfle Markus, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Schneeweiss Andreas, Schütz Florian, Wöckel Achim, Witzel Isabell, Wenz Frederik, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Luftner Diana, Loibl Sibylle, Kümmel Sherko, Diel Ingo, Dall Peter, Budach Wilfried, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Müller Volkmar, Janni Wolfgang, Jackisch Christian, Fasching Peter A, Fehm Tanja, Kühn Thorsten, Krug David, Kreipe Hans-Heinrich, Kolberg-Liedtke Cornelia, Huober Jens, Harbeck Nadia, Hanf Volker, Gerber Bernd, Friedrich Michael, Thill Marc
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
Krug D, Huober J, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Hilfrich J, Heil J, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer J, Costa S, Denkert C, Ditsch N, Gerber B, Hanusch C, Loibl S. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Ann Surg Oncol 2019; 26:3892-3901.
26.07.2019Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
26.07.2019Ann Surg Oncol 2019; 26:3892-3901
Krug David, Huober Jens, Jackisch Christian, Kümmel Sherko, Paepke Stefan, Schem Christian, Schneeweiss Andreas, Untch Michael, Debus Jürgen, von Minckwitz Gunter, Kühn Thorsten, Hilfrich Jörn, Heil Joerg, Lederer Bianca, Seither Fenja, Nekljudova Valentina, Ataseven Beyhan, Blohmer Jens-Uwe, Costa Serban Dan, Denkert Carsten, Ditsch Nina, Gerber Bernd, Hanusch Claus, Loibl Sibylle
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Hurkmans D, Mathijssen R, Aerts J, van der Leest C, van der Veldt A, Odink A, Jörger M, Debets R, Hoop E, Bins S, Wijkhuijs A, Schreurs M, Mercieca D, van Dijk T, Basak E, Koolen S. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 2019; 7:192.
19.07.2019A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
19.07.2019J Immunother Cancer 2019; 7:192
Hurkmans Daan P, Mathijssen Ron H J, Aerts Joachim G J V, van der Leest Cor H, van der Veldt Astrid A M, Odink Arlette, Jörger Markus, Debets Reno, Hoop Esther Oomen-de, Bins Sander, Wijkhuijs Annemarie J M, Schreurs Marco W J, Mercieca Darlene, van Dijk Tanja, Basak Edwin A, Koolen Stijn L W
Extent, impact, and predictors of diagnostic delay in Pompe disease: A combined survey approach to unveil the diagnostic odyssey
Lagler F, Karabul N, Rösler K, Hundsberger T, Gökce S, Mengel E, Hennermann J, Rohrbach M, Moder A, Huemer M. Extent, impact, and predictors of diagnostic delay in Pompe disease: A combined survey approach to unveil the diagnostic odyssey. JIMD Rep 2019; 49:89-95.
17.07.2019Extent, impact, and predictors of diagnostic delay in Pompe disease: A combined survey approach to unveil the diagnostic odyssey
17.07.2019JIMD Rep 2019; 49:89-95
Lagler Florian B, Karabul Nesrin, Rösler Kai M, Hundsberger Thomas, Gökce Seyfullah, Mengel Eugen, Hennermann Julia, Rohrbach Marianne, Moder Angelika, Huemer Martina
Telemedicine for Continuous Positive Airway Pressure in Sleep Apnea: A Randomized, Controlled Study
Schoch O, Baty F, Bösch M, Benz G, Niedermann J, Brutsche M. Telemedicine for Continuous Positive Airway Pressure in Sleep Apnea: A Randomized, Controlled Study. Ann Am Thorac Soc 2019
16.07.2019Telemedicine for Continuous Positive Airway Pressure in Sleep Apnea: A Randomized, Controlled Study
16.07.2019Ann Am Thorac Soc 2019
Schoch Otto, Baty Florent, Bösch Maximilian, Benz Gabriel, Niedermann Jolanda, Brutsche Martin
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
Rescigno P, Romero-Laorden N, Castro E, Saez M, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu S, Sternberg C, De Giorgi U, Olmos D, Morley C, Pezaro C, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin A, Schmid S, Caffo O, Zivi A, de Bono J. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. Eur Urol Oncol 2019
12.07.2019Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis
12.07.2019Eur Urol Oncol 2019
Rescigno Pasquale, Romero-Laorden Nuria, Castro Elena, Saez Maria I, Mehra Niven, Smeenk Stella, Sideris Spyridon, Gil Thyerry, Banks Patricia, Sandhu Shaneen K, Sternberg Cora N, De Giorgi Ugo, Olmos David, Morley Courtney, Pezaro Carmel J, Dolling David, Conteduca Vincenza, Rediti Mattia, Bianchini Diletta, Lolli Cristian, Ong Michael, Li Haoran, Omlin Aurelius, Schmid Sabine, Caffo Orazio, Zivi Andrea, de Bono Johann S
Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations
Mukherji D, Hussain H, Sayyid K, Ibrahim K, Haidar M, Zouain N, Bitar N, Alameh W, Abbas F, Faddoul S, Nemer E, Assaf G, Farhat F, Bulbul M, Temraz S, Shamseddine A, Gillessen Sommer S, Omlin A, Sakr G, El Khoury C, Youssef B, Dagher C, El-Hajj A, Nasr R, Geara F, Rabah D, Al Dousari S, Said R, Ashou R, Wazzan W, Jabbour M, Farha G, Al Hamdani N, Al Hallaq Y, Ghazal H, Dbouk H, Bachir B, Khauli R. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations. World J Urol 2019
11.07.2019Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations
11.07.2019World J Urol 2019
Mukherji Deborah, Hussain Hero K, Sayyid Khaled, Ibrahim Khaled, Haidar Mohammad, Zouain Nicolas, Bitar Nizar, Alameh Walid, Abbas Fadi, Faddoul Sami, Nemer Elie, Assaf Georges, Farhat Fadi, Bulbul Muhammad, Temraz Sally, Shamseddine Ali, Gillessen Sommer Silke, Omlin Aurelius, Sakr Ghazi, El Khoury Clement, Youssef Bassem, Dagher Christelle, El-Hajj Albert, Nasr Rami, Geara Fadi, Rabah Danny, Al Dousari Saad, Said Rabih, Ashou Raja, Wazzan Wassim, Jabbour Michel, Farha George, Al Hamdani Nibras, Al Hallaq Yousuf, Ghazal Hassan, Dbouk Haifa, Bachir Bassel, Khauli Raja
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Di Cosimo S, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud F, Apolone G, Verderio P, Huober J, Daidone M, Peña L, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Tagliabue E. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur J Cancer 2019; 118:1-9.
05.07.2019The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
05.07.2019Eur J Cancer 2019; 118:1-9
Di Cosimo Serena, Gori Stefania, Cinieri Saverio, Torri Valter, Baselga José, Piccart Martine, de Braud Filippo G, Apolone Giovanni, Verderio Paolo, Huober Jens, Daidone Maria Grazia, Peña Lorena de la, Triulzi Tiziana, Pizzamiglio Sara, De Cecco Loris, de Azambuja Evandro, Fumagalli Debora, Putzai Lajos, Harbeck Nadia, Izquierdo Miguel, Tagliabue Elda
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019; 5:1043-1047.
01.07.2019Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
01.07.2019JAMA Oncol 2019; 5:1043-1047
Berner Fiamma, Hartmann Fabienne, Cheng Hung-Wei, Hönger Gideon, Recher Mike, Goldman Jonathan, Cozzio Antonio, Früh Martin, Neefjes Jacques, Driessen Christoph, Ludewig Burkhard, Hegazy Ahmed N, Jochum Wolfram, Speiser Daniel E, Zippelius Alfred, Läubli Heinz, Bomze David, Diem Stefan, Ali Omar Hasan, Fässler Mirjam, Ring Sandra, Niederer Rebekka, Ackermann Christoph J, Baumgaertner Petra, Pikor Natalia, Cruz Cristina Gil, van de Veen Willem, Akdis Mübeccel, Nikolaev Sergey, Flatz Lukas